Acupoint Application Combined With 5-HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: A Single-Center, Randomized, Controlled Trial
This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.
• Pathologically or cytologically confirmed lung cancer.
• Scheduled to receive first-line platinum-based chemotherapy.
• Aged 18 to 75 years.
• Karnofsky Performance Status (KPS) score ≥ 60.
• Expected survival ≥ 3 months.
• Voluntarily signed written informed consent.